CD274 and hepatocellular carcinoma: Recently, another ICI-based therapeutic combination, tremelimumab (anti-CTLA-4 antibody) plus durvalumab (anti-PD-L1 antibody), has been approved as first-line treatment for unresectable HCC [5].